Mutations in TP53 predominated, occurring in at least 96% of high-grade serous ovarian cancer samples; furthermore, BRCA1 and BRCA2 were mutated in 22% of the tumors, owing to a combination of germline and somatic mutations. The gene discussed is TP53; the disease is ovarian serous adenocarcinoma.